Achyut Healthcare Ltd vs Krebs Biochemicals Industries Ltd Stock Comparison
Achyut Healthcare Ltd vs Krebs Biochemicals Industries Ltd Stock Comparison
Last Updated on: May 05, 2026
Key Highlights
The Latest Trading Price of Achyut Healthcare Ltd is ₹ 5.26 as of 05 May 15:30
. The P/E Ratio of Achyut Healthcare Ltd changed from 342.5 on March 2022 to 163 on March 2025 . This represents a CAGR of -16.94% over 4 yearsThe P/E Ratio of Krebs Biochemicals & Industries Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Achyut Healthcare Ltd changed from ₹ 13.85 crore on March 2022 to ₹ 76.79 crore on March 2025 . This represents a CAGR of 53.45% over 4 yearsThe Market Cap of Krebs Biochemicals & Industries Ltd changed from ₹ 174.33 crore on March 2021 to ₹ 144 crore on March 2025 . This represents a CAGR of -3.75% over 5 years The revenue of Achyut Healthcare Ltd for the Dec '25 is ₹ 1.61 crore as compare to the Sep '25 revenue of ₹ 2.66 crore. This represent the decline of -39.47% The revenue of Krebs Biochemicals & Industries Ltd for the Dec '25 is ₹ 7.28 crore as compare to the Sep '25 revenue of ₹ 4.17 crore. This represent the growth of 74.58% The ebitda of Achyut Healthcare Ltd for the Dec '25 is ₹ 0.04 crore as compare to the Sep '25 ebitda of ₹ 0.19 crore. This represent the decline of -78.95% The ebitda of Krebs Biochemicals & Industries Ltd for the Dec '25 is ₹ 0.3 crore as compare to the Sep '25 ebitda of ₹ -2.79 crore. This represent the decline of -110% The net profit of Achyut Healthcare Ltd changed from ₹ 0.03 crore to ₹ 0 crore over 5 quarters. This represents a CAGR of -100.00%
The net profit of Krebs Biochemicals & Industries Ltd changed from ₹ -5.17 crore to ₹ -3.13 crore over 7 quarters. This represents a CAGR of -24.93%
The Dividend Payout of Achyut Healthcare Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Krebs Biochemicals & Industries Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .
About Achyut Healthcare Ltd
Achyut Healthcare Limited was incorporated as Achyut Securities Private Limited' on January 11, 1996 as a Private Limited Company under the Companies Act, 1956 with the Registrar of Companies, Gujarat, Dadra and Nagar Haveli.
The Company name was changed to Achyut Healthcare Private Limited', and a fresh Certificate of Incorporation dated November 26, 2002.
Subsequently, the Company got converted from a Private Limited to Public Limited and the name of the Company changed to Achyut Healthcare Limited', and a fresh Certificate of Incorporation dated November 30, 2021 was issued to the Company by Registrar of Companies, Gujarat at Ahmedabad.
The Company is engaged in trading of Cenzure, Arpimune, Azathioprine IP, Everolimus, Mycophenolate Mofetil USP, Mycophenolate Sodium USP, Sirolimus, Tacrolimus USP, Infrared thermometer, Ascorbic Acid Coated Vitamin C, Calcium carbonate oyster, Cellulose acetate Phthalate, Chlorthalidone IP, Croscarmellose Sodium IP/USP, DIBasic Calcium Phosphate IP, DIEthyl Phthalate, Diltiazem Hydrochloride IP, Easy Coat Fc Titanium Dioxide, Escitalopram IP, Escitalopram Oxalate, Favipiravir among many other products.
About Krebs Biochemicals & Industries Ltd
Krebs Biochemicals & Industries Limited was initially incorporated as 'Krebs Biochemicals Limited' in 1991.
The name of the Company was changed from Krebs Biochemicals Limited to Krebs Biochemicals & Industries Limited effected from November 21, 2003.
Promoted by R T Ravi, Company engages in manufacture of Active Pharmaceutical Ingredients(API) through Fermentation process, one among very few in the world to do the same.
The Company develops commercially viable biotech processes for application in medicine, agriculture and industry.
Undertaking contract manufacturing for large pharmaceutical and multinational companies and developing products for sale in global markets, the Company possesses expertise and infrastructure in chemical synthesis, fermentation and enzymatic technologies.
KBIL which commenced commercial operations in the year 1994 with an installed capacity of 60 TPA has now grown to 150 TPA.
FAQs for the comparison of Achyut Healthcare Ltd and Krebs Biochemicals & Industries Ltd
Which company has a larger market capitalization, Achyut Healthcare Ltd or Krebs Biochemicals & Industries Ltd?
Market cap of Achyut Healthcare Ltd is 123 Cr while Market cap of Krebs Biochemicals & Industries Ltd is 127 Cr
What are the key factors driving the stock performance of Achyut Healthcare Ltd and Krebs Biochemicals & Industries Ltd?
The stock performance of Achyut Healthcare Ltd and Krebs Biochemicals & Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Achyut Healthcare Ltd and Krebs Biochemicals & Industries Ltd?
As of May 5, 2026, the Achyut Healthcare Ltd stock price is INR ₹5.26. On the other hand, Krebs Biochemicals & Industries Ltd stock price is INR ₹58.92.
How do dividend payouts of Achyut Healthcare Ltd and Krebs Biochemicals & Industries Ltd compare?
To compare the dividend payouts of Achyut Healthcare Ltd and Krebs Biochemicals & Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.